New gene-silencing drug aims to lower bad cholesterol without permanent DNA changes

NCT ID NCT07428473

Recruiting now Disease control Sponsor: Monash University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This early-stage study tests STX-1150, a new medicine that temporarily turns off a gene (PCSK9) in the liver to lower bad cholesterol (LDL-C). It does not change your DNA. Up to 64 adults with high LDL-C will receive one or more doses and be followed for a year. The main goal is to check safety and how well the drug works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ELEVATED LDL-C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis cardiovascular disorder Hypercholesterolemia hyperlipidemia hypertensive disorder myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ELEVATED LDL-C ELEVATED LDL-C AND HIGH CHOLESTEROL

Contacts and locations

Locations

Monash Health/ Victorian Heart Hospital (VHH)
RECRUITING

Clayton, Victoria, 3168, Australia
New Zealand Clinical Research (NZCR)
NOT_YET_RECRUITING

Christchurch, Christchurch, 8011, New Zealand